1 September 2012 in Reports of Practical Oncology and Radiotherapy
The primary objective of this study was to assess whether there was an improvement in QoL for patients with brain metastases after radiotherapy treatments. Assessment of quality of life (QoL) in brain metastasis patients has become increasingly recognized as an important outcome. Patients treated for brain metastasis in our department during 2010 were included in our prospective study. QoL assessments were conducted at baseline, 1 month, and 3 months after completion of whole-brain radiotherapy (WBRT). Wilcoxon test for multiple comparisons was calculated to detect significant differences in global QoL scores. Thirty-nine patients with brain metastases completed the EORTC QLQ-C30/BN-20 questionnaire independently. Median age was 59.9 years (from 37 to 81 years). Our results report differences between the baseline and 3 months in worsening of a global health status (p = 0.034) and cognitive function (p = 0.004), as well as drowsiness (p = 0.001), appetite loss (p = 0.031) and hair loss (p = 0.005). There is a tendency for deterioration of physical function (p = 0.004), communication deficit (p = 0.012), and weakness of legs (p = 0.024), between the baseline and 1 month evaluation. There was no difference in a global cognitive status between different evaluations. Median survival time was 3 months (CI 95% 1.85; 4.15). Our findings indicate a small deterioration for a global QoL status, and large deterioration for cognitive function after radiation treatments, as well as worsening of brain metastasis related symptom items. Further research is necessary to refine treatment selection for patients with brain metastases, since it may at least contribute to the stabilization of their QoL status.
1 September 2011 in European Journal of Cancer
20 May 2010 in Journal of Clinical Oncology
E15514 Background: Chemoradiation of the cervix is the standard treatment for locally advanced disease. The data concerning survivors of cervix chemoradiation are scarce. Our objective is to study quality of life (QoL) in these patients using a validated scale. Methods: Design: case-control study. Case group: All (135) cervical cancer survivors treated with chemoradiation, from November 2000-September 2002, in our Institute. All pts included were required to have a minimum follow up without relapse of 18 months. Women were contacted by telephone and invited to participate in the study. Control group: healthy women matched for age were recruited in the Breast Cancer Evaluation Clinic of our institution. The questionnaire was self-administered. Instruments: The Portuguese translated and validated version of the Functional Assessment of Chronic Illness Therapy-Cervix Cancer Questionnaire (FACT-Cx, 4th version) was used. This scale combines a Global QoL assessment (FACT-G) and a Cervix Cancer subscale (CxCs). A trial outcome index (TOI) combines the CxCs with the Physical (PWB) and Functional (FWB) well-being subscales of FACT-G. The other FACT-G subscales are Emocional (EWB) and Social well-being (SWB). Results: From 135 eligible pts, 69 cases (51%) agreed to participate in the study and 69 controls were also recruited. Preliminary analysis: median age for cases and controls is 56 (37-81) and 53.5 (34-74) respectively. Medium follow-up for cases is 40.6 months (20.8-58.2). FACT-G total score was 77.98 and 79.65 for cases and controls respectively (p = 0.63). FACT-G subscales (Cases vs Controls): PWB- 22.48 vs. 23.95 (p = 0.1) SWB: 19.77 vs. 18.58 (p = 0.86); EWB- 17.47 vs.17.52 (p = 0.94) and FWB-18.29 vs. 19.12 (p = 0.39). FACT-Cx total score: 40.30 vs. 43.32 (p = 0.03) and FACT-Cx TOI score: 81.08 vs 86.97 for cases and controls respectively (p = 0.03). Conclusions: General quality of life of our cases was not significantly different from the control group (including specific subscales). However when considering disease-specific scales cervix cancer survivors treated with chemoradiation showed significantly worse QoL than controls. No significant financial relationships to disclose.
1 September 2007 in European Journal of Cancer Supplements
1 September 2012 in Annals of Oncology